Main| Contact Us| BP Claims| Site Map
Ask Attorney Logo Call Ask Attorney
Home | Accidents | Diseases | Drugs & Devices | Medical Malpractice | Products Liability | Other | Pollutants |
Drugs & Devices > Renu MultiPlus Solution

Bausch and Lomb is responsible for contact lens wearers suffering from corneal infection from fungal eye disease.

According to data released by the Centers for Disease Control and Prevention (CDC) five kinds of contact lens solution, three of which are made by Bausch & Lomb were used by people suffering from an aggressive fungal eye infection.

All ReNu solutions sold in North America are made at one Bausch and Lomb manufacturing plant located in Greenville, S.C.

The CDC has received reports of 86 confirmed, nine possible, and 96 suspected fusarium keratitis cases in 29 states. The infections by the ReNu-induced fusarium fungus were so severe that at least eight patients have required corneal transplants. At least 54 of the 58 contact lens wearers stated that they had used a Bausch & Lomb lens cleaning solution. Bausch and Lomb is responsible as these cases could have been avoided if Bausch & Lomb advised the contact-wearing public of the problem earlier. These figures exclude additional cases being investigated in Asia, which is also supplied with ReNu contact lens solutions from the same South Carolina plant.

Since March 2006, the CDC and FDA have been investigating a possible connection between Bausch & Lomb contact lens solutions and an international outbreak of sight-threatening eye infections, called fusarium (fungal) keratitis. Contact lens wearers with symptoms such as redness, pain, light sensitivity, or blurry vision are urged to see a doctor.

The FDA said the recall of ReNu moisture loc by Bausch and Lomb is based on the disproportionate number of cases compared to the overall market share. Renu moisture loc was used by 57 percent of the outbreak victims.

In contrast, ReNu MultiPlus solution for contact lens wearers was reported as being used by 27 percent of the outbreak victims. ReNu MultiPlus is used by 40 percent of the U.S. market or 11 million consumers.

ReNu MultiPlus has been on the market since 1997 and has a different chemical makeup than ReNu moisture loc, which has only been sold in the United States since late 2004.

Free Case Review

Renu MultiPlus Solution
  Abacavir |   ACE Inhibitors |   Advil |   Ambien |   Avandia |   Botox |   Celexa |   Chantix |   Cymbalta |   Cytotec |   Desmopressin |   Diabetes and Seroquel |   Dilantin |   Duragesic Patch |   Fentanyl |   Erythropoiesis-Stimulating Agents (ESAs) |   Fleet Enema |   Fosamax |   Gadolinium |   Gardasil |   Heart Attack and Avandia |   Heparin |   Hydroxycut |   Kugel Mesh Patch |   Levaquin |   Levitra |   Meridia |   Motrin |   Neurontin |   NuvaRing |   Ortho Evra Patch |   Oxycontin |   Paxil |   Paxil & Breast Cancer |   Prempro |   Prozac |   Raptiva |   Reglan |   ReNu Contact Solution |   Ritalin |   Renu MultiPlus Solution |   Serevent |   Seroquel |   Shoulder Surgery and Pain Pump |   Singulair |   Tequin |   Tiazac |   Trasylol |   Viagra |   Vytorin |   Wellbutrin |   Xenadrine RFA-1 |   Xigris |   Xolair |   Yaz |   Zelnorm |   Zevalin |   Zicam |   Zithromax |   Zoloft |   Zometa |   Zyprexa | Call Now (800) 780-2686

Home| Accidents| Diseases| Drugs & Devices| Medical Malpractice| Products Liability| Other| Pollutants| Conatct Us | Site Map